transdermal glp-1 receptor agonist patch clinical trial Single-Administration Self-Boosting Microneedle for The Treatment of Obesity GLP-1 receptor agonists and next-generation
Description
Tang H, et al
Mechanisms of muscle loss associated with GLP-1RAs treatment Preservation of skeletal muscle is critical for metabolic health, physical function and long-term outcomes, making the study of mechanisms underlying muscle loss during GLP-1RA therapy clinically relevant
Although a GLP-1R agonist does not alter alcohol intake in AUD patients, it reduces this consumption in a sub-population of obese AUD individuals
A meta-analysis across randomized controlled trials found significant reductions in body weight averaging 12.4%, BMI by 4.0 kg/m2, and waist circumference by 8.0 cm
Consistently, the E288 45.52b T mutation in GIPR reduced retatrutide-induced cAMP accumulation by 3.0-fold
Health experts say you should always look at your own health history when thinking about these treatments
